LAVA Therapeutics NV LVTX 深 滬
等待開盤 10-03 09:30:00 美东时间
1.55
+0.010
+0.65%
華盛通- 最 高1.56
- 今 開1.55
- 成交量 37.78万股
- 最 低 1.54
- 昨 收 1.54
- 總市值 4077.32万
- 52周最高 2.093
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.8502
- 委 比 18.84%
- 總股本 2630.53万
- 歷史最高 17.20
- 量 比 1.15
- 振 幅 1.30%
- 歷史最低 0.8502
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
XOMA Royalty and LAVA announce the extension of the tender offer for LAVA shares until October 17, 2025, originally set for October 3. The offer includes cash and a contingent value right (CVR) per share. The transaction is expected to close in Q4 2025, subject to 80% (or 75% in certain cases) of shares being tendered, shareholder approval, and other customary conditions. LAVA shareholders who have already tendered shares do not need to re-tender...
10-02 20:43
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025
LAVA Therapeutics has canceled its Extraordinary General Meeting (EGM) scheduled for September 30, 2025, to allow further discussions with XOMA Royalty regarding the terms of their proposed transaction. Both companies remain committed to completing the deal, which is now anticipated to close in the fourth quarter of 2025. The EGM will be reconvened by early November, with details to be announced later. The cancellation aims to address potential l...
09-30 11:00
4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week
Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stock Rankings witnessing a significant decline.
09-03 18:21
美股大行评级 | 潜在涨幅345.51%！BTIG上调Syndax Pharmaceuticals目标价至56美元，维持"买入"评级
今日重点评级关注：BTIG：维持Syndax Pharmaceuticals"买入"评级，目标价从43美元升至56美元；花旗：维持Syndax Pharmaceuticals"买入"评级，目标价从46美元升至51美元
08-06 09:30
Jefferies Downgrades LAVA Therapeutics to Hold, Lowers Price Target to $1.5
Jefferies analyst Roger Song downgrades LAVA Therapeutics (NASDAQ:LVTX) from Buy to Hold and lowers the price target from $3 to $1.5.
08-05 18:43
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, HNI, LVTX, HLVX on Behalf of Shareholders
NEW YORK, Aug. 4, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or ...
08-05 00:23
LAVA Therapeutics Agrees to Acquisition by XOMA
The latest announcement is out from LAVA Therapeutics ( ($LVTX) ). On August 3,...
08-04 19:58
JMP Securities Reiterates Market Perform on LAVA Therapeuticsto Market Perform
JMP Securities analyst Reni Benjamin reiterates LAVA Therapeutics (NASDAQ:LVTX) from Market Perform to Market Perform.
05-15 22:08
LAVA Therapeutics Q1 EPS $(0.13) Beats $(0.38) Estimate
LAVA Therapeutics (NASDAQ:LVTX) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.38) by 65.79 percent. This is a 550 percent decrease over losses of $(0.02) per share from
05-14 19:40
美股大行评级 | 潜在涨幅778.38%！HC Wainwright & Co.上调BioLine Rx目标价至26美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1113752959213998081.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持BioLine Rx(BLRX)"买入"评级，目标价从9美元升至26美元</p> <p>• 德银：上调固特异轮胎橡胶(GT)评级至"买入"，目标价13美元</p> <p
04-01 09:48
